{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=27&state=Kentucky",
    "query": {
      "state": "Kentucky",
      "city": "Lexington",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 4514,
    "total_pages": 452,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=28&state=Kentucky&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=26&state=Kentucky&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T06:01:16.677Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05225415",
      "title": "Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia With Lewy Bodies"
      ],
      "interventions": [
        {
          "name": "CT1812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cognition Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 130,
      "start_date": "2022-05-19",
      "completion_date": "2024-11-25",
      "has_results": true,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05225415"
    },
    {
      "nct_id": "NCT00354835",
      "title": "Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Rhabdomyosarcoma",
        "Childhood Alveolar Rhabdomyosarcoma",
        "Childhood Botryoid-Type Embryonal Rhabdomyosarcoma",
        "Childhood Embryonal Rhabdomyosarcoma",
        "Localized Childhood Soft Tissue Sarcoma",
        "Rhabdomyosarcoma",
        "Sarcoma",
        "Stage I Adult Soft Tissue Sarcoma AJCC v7",
        "Stage II Adult Soft Tissue Sarcoma AJCC v7",
        "Stage III Adult Soft Tissue Sarcoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dactinomycin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "Up to 49 Years"
      },
      "enrollment_count": 481,
      "start_date": "2006-12-26",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 196,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354835"
    },
    {
      "nct_id": "NCT01993225",
      "title": "A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Androxal 12.5 mg/25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsules",
          "type": "DRUG"
        },
        {
          "name": "AndroGel 1.62%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repros Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2014-01",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-01",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Garden City",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01993225"
    },
    {
      "nct_id": "NCT02048917",
      "title": "Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "High Intensity Counseling + Long Acting NRT + PRN NRT",
          "type": "DRUG"
        },
        {
          "name": "High Intensity Counseling + bupropion + PRN NRT",
          "type": "DRUG"
        },
        {
          "name": "High Intensity Counseling + varenicline + PRN NRT",
          "type": "DRUG"
        },
        {
          "name": "High Intensity Counseling + Long Acting NRT",
          "type": "DRUG"
        },
        {
          "name": "High Intensity Counseling + bupropion",
          "type": "DRUG"
        },
        {
          "name": "High Intensity Counseling + varenicline",
          "type": "DRUG"
        },
        {
          "name": "Low Intensity Counseling + Long Acting NRT + PRN NRT",
          "type": "DRUG"
        },
        {
          "name": "Low Intensity Counseling + bupropion + PRN NRT",
          "type": "DRUG"
        },
        {
          "name": "Low Intensity Counseling + varenicline + PRN NRT",
          "type": "DRUG"
        },
        {
          "name": "Low Intensity Counseling + Long Acting NRT",
          "type": "DRUG"
        },
        {
          "name": "Low Intensity Counseling + bupropion",
          "type": "DRUG"
        },
        {
          "name": "Low Intensity Counseling + varenicline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kentucky",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2014-07-22",
      "completion_date": "2019-05-15",
      "has_results": false,
      "last_update_posted_date": "2020-01-29",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 10,
      "location_summary": "Ashland, Kentucky • Elizabethtown, Kentucky • Hazard, Kentucky + 5 more",
      "locations": [
        {
          "city": "Ashland",
          "state": "Kentucky"
        },
        {
          "city": "Elizabethtown",
          "state": "Kentucky"
        },
        {
          "city": "Hazard",
          "state": "Kentucky"
        },
        {
          "city": "Hazard",
          "state": "Kentucky"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048917"
    },
    {
      "nct_id": "NCT03772730",
      "title": "Patient-Specific Precision Injury Signatures in Multiply Injured Orthopaedic Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pelvic, Acetabular, Femur, or Diaphyseal Tibial Operative Orthopaedic Injuries"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Major Extremity Trauma Research Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 320,
      "start_date": "2019-03-20",
      "completion_date": "2023-05-30",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Indianapolis, Indiana • Lexington, Kentucky + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03772730"
    },
    {
      "nct_id": "NCT06587828",
      "title": "A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autoimmune Diseases",
        "Ulcerative Colitis",
        "Multiple Sclerosis",
        "Scleroderma",
        "Ankylosing Spondylitis",
        "Celiac Disease",
        "Non-radiographic Axial Spondyloarthritis (Nr-axSpA)",
        "Crohn&Amp;#39;s Disease",
        "Birdshot Chorioretinitis"
      ],
      "interventions": [
        {
          "name": "Companion blood samples with procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 238,
      "start_date": "2023-01-03",
      "completion_date": "2026-09-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 11,
      "location_summary": "Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06587828"
    },
    {
      "nct_id": "NCT02313909",
      "title": "Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Acetylsalicylic acid (Aspirin, BAY1019036)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban-Placebo",
          "type": "OTHER"
        },
        {
          "name": "Aspirin-Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 7213,
      "start_date": "2014-12-23",
      "completion_date": "2018-02-15",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 38,
      "location_summary": "Tucson, Arizona • Long Beach, California • Stanford, California + 32 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02313909"
    },
    {
      "nct_id": "NCT06731907",
      "title": "A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "HER3-DXd",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-03-30",
      "completion_date": "2032-03-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 5,
      "location_summary": "Lexington, Kentucky • Baltimore, Maryland • Fargo, North Dakota + 2 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06731907"
    },
    {
      "nct_id": "NCT03459287",
      "title": "Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "INTERCEPT",
          "type": "DEVICE"
        },
        {
          "name": "Control",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cerus Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "11 Years and older"
      },
      "enrollment_count": 581,
      "start_date": "2018-12-05",
      "completion_date": "2024-03-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Stanford, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03459287"
    },
    {
      "nct_id": "NCT00096993",
      "title": "A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 131,
      "start_date": "2005-01",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2015-06-10",
      "last_synced_at": "2026-10-22T06:01:16.677Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096993"
    }
  ]
}